Oslo, Norway, 15 December 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. Today the Company received a positive response from the Norwegian Research Council (NRC), offering NOK 16 mill to take our lead product APC148 through early-stage clinical testing.
Adjutec will apply for starting a first-in-man study with our lead product APC148 alone early 2024. This study will give important safety data and is the first of several phase 1 studies to investigate the antibiotic and enzyme inhibitor (APC148) doses to be combined. The grant will support these clinical trials as well as further microbiology testing of multi-resistant bacteria and in-vivo safety testing.
“This award is fantastic news that will secure fast-track development of our lead product APC148. APC148 combined with antibiotics, restores efficacy against multidrug resistant bacteria. Obtaining clinical phase 1 safety data will take the company to an important inflexion point, making the project attractive to international pharma. The grant is a great external evaluation of the science and medical need for our novel antibiotic product”, comments Bjørn Klem, CEO of AdjuTec Pharma.
Full PR available here